Definition of prostaglandin E2-EP2 signals in the colon tumor microenvironment that amplify inflammation and tumor growth

Cancer Research

Volumn 75, Issue 14, 2015, Pages 2822-2832

  Ma, Xiaojun ^a   Aoki, Tomohiro ^a   Tsuruyama, Tatsuaki ^a   Narumiya, Shuh ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 FLUOROBENZOYL) 3 [(6 METHOXY 2 NAPHTHYL)OXY]METHYLAZETIDINE 3 CARBOXYLIC ACID; CXCL1 CHEMOKINE; CYCLOOXYGENASE 2; INTERLEUKIN 6; PROSTAGLANDIN E RECEPTOR 1; PROSTAGLANDIN E RECEPTOR 2; PROSTAGLANDIN E RECEPTOR 3; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; WNT5A PROTEIN; PROSTAGLANDIN E2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW; CELL POPULATION; CHEMOPROPHYLAXIS; COLON CARCINOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; FIBROBLAST CULTURE; HUMAN; HUMAN CELL; INFLAMMATION; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR MICROENVIRONMENT; ULCERATIVE COLITIS; ANIMAL; C57BL MOUSE; CARCINOGENESIS; CELL CULTURE; CELL PROLIFERATION; COLITIS; COLONIC NEOPLASMS; COMPLICATION; DRUG EFFECTS; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ANIMALS; CARCINOGENESIS; CELL PROLIFERATION; CELLS, CULTURED; COLITIS; COLONIC NEOPLASMS; DINOPROSTONE; FEMALE; HUMANS; INFLAMMATION; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTORS, PROSTAGLANDIN E, EP2 SUBTYPE; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84942903147     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-0125     Document Type: Article

References (50)

1. Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet 2014; 383: 1490-502.
2. Beaugerie L, Svrcek M, Seksik P, Bouvier AM, Simon T, Allez M, et al. Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease. Gastroenterology 2013; 145: 166-75 e8.
3. Janne PA, Mayer RJ. Chemoprevention of colorectal cancer. N Engl J Med 2000; 342: 1960-8.
4. Bosetti C, Rosato V, Gallus S, Cuzick J, La Vecchia C. Aspirin and cancer risk: a quantitative review to 2011. Ann Oncol 2012; 23: 1403-15.
5. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011; 377: 31-41.
6. Brown JR, DuBois RN. COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol 2005; 23: 2840-55.
7. Venerito M, Wex T, Malfertheiner P. Nonsteroidal anti-inflammatory drug-induced gastroduodenal bleeding: risk factors and prevention strategies. Pharmaceuticals 2010; 3: 2225-37.
8. Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 2006; 116: 4-15.
9. Rigas B, Goldman IS, Levine L. Altered eicosanoid levels in human colon cancer. J Lab Clin Med 1993; 122: 518-23.
10. 2 pathway: key rolesin the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 2009; 30: 377-86.
11. Peddareddigari VG, Wang D, Dubois RN. The tumor microenvironment in colorectal carcinogenesis. Cancer Microenviron 2010; 3: 149-66.
12. Sugimoto Y, Narumiya S. Prostaglandin E receptors. J Biol Chem 2007; 282: 11613-7.
13. Tanaka T, Kohno H, Suzuki R, Yamada Y, Sugie S, Mori H. A novel inflammation-related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate. Cancer Sci 2003; 94: 965-73.
14. Kabashima K, Saji T, Murata T, Nagamachi M, Matsuoka T, Segi E, et al. The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut. J Clin Invest 2002; 109: 883-93.
15. af Forselles KJ, Root J, Clarke T, Davey D, Aughton K, Dack K, et al. In vitro and in vivo characterization of PF-04418948, a novel, potent and selective prostaglandin EP2 receptor antagonist. Br J Pharmacol 2011; 164: 1847-56.
16. Segi E, Sugimoto Y, Yamasaki A, Aze Y, Oida H, Nishimura T, et al. Patent ductus arteriosus and neonatal death in prostaglandin receptor EP4-deficient mice. Biochem Biophys Res Commun 1998; 246: 7-12.
17. Samuelsson B, Morgenstern R, Jakobsson PJ. Membrane prostaglandin E synthase-1: a novel therapeutic target. Pharmacol Rev 2007; 59: 207-24.
18. Boivin GP, Washington K, Yang K, Ward JM, Pretlow TP, Russell R, et al. Pathology of mouse models of intestinal cancer: consensus report and recommendations. Gastroenterology 2003; 124: 762-77.
19. Daley JM, Thomay AA, Connolly MD, Reichner JS, Albina JE. Use of Ly6G-specific monoclonal antibodytodeplete neutrophils inmice. JLeukoc Biol 2008; 83: 64-70.
20. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006; 6: 392-401.
21. Ralfkiaer E, Pulford KA, Lauritzen AF, Avnstrom S, Guldhammer B, Mason DY. Diagnosis of acute myeloid leukaemia with the use of monoclonal anti-neutrophil elastase (NP57) reactive with routinely processed biopsy samples. Histopathology 1989; 14: 637-43.
22. Pulford KA, Erber WN, Crick JA, Olsson I, Micklem KJ, Gatter KC, et al. Use of monoclonal antibody against human neutrophil elastase in normal and leukaemic myeloid cells. J Clin Pathol 1988; 41: 853-60.
23. Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S, et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009; 15: 103-13.
24. Popivanova BK, Kitamura K, Wu Y, Kondo T, Kagaya T, Kaneko S, et al. Blocking TNF-α in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest 2008; 118: 560-70.
25. Onizawa M, Nagaishi T, Kanai T, Nagano K, Oshima S, Nemoto Y, et al. Signaling pathway via TNF-a/NF-kB in intestinal epithelial cells may be directly involved in colitis-associated carcinogenesis. Am J Physiol Gastrointest Liver Physiol 2009; 296: G850-9.
26. Collart MA, Baeuerle P, Vassalli P. Regulation of tumor necrosis factor a transcription in macrophages: involvement of four kB-like motifs and of constitutive and inducible forms of NF-kB. Mol Cell Biol 1990; 10: 1498-506.
27. Libermann TA, Baltimore D. Activation of interleukin-6 gene expression through the NF-kB transcription factor. Mol Cell Biol 1990; 10: 2327-34.
28. Crofford LJ, Tan B, McCarthy CJ, Hla T. Involvement of nuclear factor kB in the regulation of cyclooxygenase-2 expression by interleukin-1 in rheumatoid synoviocytes. Arthritis Rheum 1997; 40: 226-36.
29. Iliopoulos D, Jaeger SA, Hirsch HA, Bulyk ML, Struhl K. STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell 2010; 39: 493-506.
30. Iliopoulos D, Hirsch HA, Struhl K. An epigenetic switch involving NF-kB, Lin28, Let-7 Micro RNA, and IL6 links inflammation to cell transformation. Cell 2009; 139: 693-706.
31. Aoki T, Narumiya S. Prostaglandins and chronic inflammation. Trends Pharmacol Sci 2012; 33: 304-11.
32. Oppenheim JJ, Zachariae CO, Mukaida N, Matsushima K. Properties of the novel proinflammatory supergene "intercrine" cytokine family. Annu Rev Immunol 1991; 9: 617-48.
33. 2-stimulated intestinal epithelial proliferation and angiogenesis. Cancer Res 2006; 66: 846-55.
34. Ostman A, Augsten M. Cancer-associated fibroblasts and tumor growth-bystanders turning into key players. Curr Opin Genet Dev 2009; 19: 67-73.
35. Lichtenstein GR, Hanauer SB, Sandborn WJ, Practice Parameters Committee of American College of G. Management of Crohn's disease in adults. Am J Gastroenterol 2009; 104: 465-83; quiz 64, 84.
36. Garrity-Park MM, Loftus EV Jr, Bryant SC, Sandborn WJ, Smyrk TC. Tumor necrosis factor-a polymorphisms in ulcerative colitis-associated colorectal cancer. Am J Gastroenterol 2008; 103: 407-15.
37. Katoh H, Wang D, Daikoku T, Sun H, Dey SK, Dubois RN. CXCR2-expressing myeloid-derived suppressor cells are essential to promote colitis-associated tumorigenesis. Cancer Cell 2013; 24: 631-44.
38. Jamieson T, Clarke M, Steele CW, Samuel MS, Neumann J, Jung A, et al. Inhibition of CXCR2 profoundly suppresses inflammation-driven and spontaneous tumorigenesis. J Clin Invest 2012; 122: 3127-44.
39. Zagani R, Hamzaoui N, Cacheux W, de Reynies A, Terris B, Chaussade S, et al. Cyclooxygenase-2 inhibitors down-regulate osteopontin and Nr4A2-new therapeutic targets for colorectal cancers. Gastroenterology 2009; 137: 1358-66 e1-3.
40. 2 promotes Th1 differentiation via synergistic amplification of IL-12 signalling by cAMP and PI3-kinase. Nat Commun 2013; 4: 1685.
41. Kumar S, Sharma P, Kumar D, Chakraborty G, Gorain M, Kundu GC. Functional characterization of stromal osteopontin in melanoma progression and metastasis. PLoS ONE 2013; 8: e69116.
42. Agrawal D, Chen T, Irby R, Quackenbush J, Chambers AF, Szabo M, et al. Osteopontin identified ascolon cancer tumor progression marker. CR Biol 2003; 326: 1041-3.
43. 716 knockout mice. Nat Med 2001; 7: 1048-51.
44. 2 signaling promotes tumor cell survival and proliferation in childhood neuroblastoma. PLoS ONE 2012; 7: e29331.
45. 2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proc Natl Acad Sci U S A 2004; 101: 591-6.
46. Jimenez P, Piazuelo E, Cebrian C, Ortego J, Strunk M, Garcia-Gonzalez MA, et al. Prostaglandin EP2 receptor expression is increased in Barrett's oesophagus and oesophageal adenocarcinoma. Aliment Pharmacol Ther 2010; 31: 440-51.
47. Chell SD, Witherden IR, Dobson RR, Moorghen M, Herman AA, Qualtrough D, et al. Increased EP4 receptor expression in colorectal cancer progression promotes cell growth and anchorage independence. Cancer Res 2006; 66: 3106-13.
48. Kitamura T, Itoh M, Noda T, Tani K, Kobayashi M, Maruyama T, et al. Combined effects of prostaglandin E receptor subtype EP1 and subtype EP4 antagonists on intestinal tumorigenesis in adenomatous polyposis coli gene knockout mice. Cancer Sci 2003; 94: 618-21.
49. Hizaki H, Segi E, Sugimoto Y, Hirose M, Saji T, Ushikubi F, et al. Abortive expansion of the cumulus and impaired fertility in mice lacking the prostaglandin E receptor subtype EP2. Proc Natl Acad Sci U S A 1999; 96: 10501-6.
50. 2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res 2007; 67: 4507-13.